ECS Botanics to Supply Capsules for Trial Studying Potential of Medicinal Cannabis in Patients with Obstructive Sleep Apnea

MT Newswires Live

2025/07/07

ECS Botanics Holdings (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of Western Australia, to assess the therapeutic potential of medicinal cannabis in patients with clinically-significant obstructive sleep apnea, according to a Monday Australian bourse filing.

It will examine the impact of 10 milligrams of tetrahydrocannabinol on obstructive sleep apnea severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes.

The trial targets the enrollment of 24 participants and is expected to open within the year. Recruitment is expected to begin in July.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2549430799"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549430799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549430799?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-07 14:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549430799","market":"fut","top_or_hot":-1,"title":"ECS Botanics to Supply Capsules for Trial Studying Potential of Medicinal Cannabis in Patients with Obstructive Sleep Apnea","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ECSDD.AU\">ECS Botanics Holdings</a> (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of <a href=\"https://laohu8.com/S/WER.AU\">Western Australia</a>, to assess the therapeutic potential of medicinal cannabis in patients with clinically-significant obstructive sleep apnea, according to a Monday Australian bourse filing.</p><p>It will examine the impact of 10 milligrams of tetrahydrocannabinol on obstructive sleep apnea severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes.</p><p>The trial targets the enrollment of 24 participants and is expected to open within the year. Recruitment is expected to begin in July.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ECS Botanics to Supply Capsules for Trial Studying Potential of Medicinal Cannabis in Patients with Obstructive Sleep Apnea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nECS Botanics to Supply Capsules for Trial Studying Potential of Medicinal Cannabis in Patients with Obstructive Sleep Apnea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-07 14:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ECSDD.AU\">ECS Botanics Holdings</a> (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of <a href=\"https://laohu8.com/S/WER.AU\">Western Australia</a>, to assess the therapeutic potential of medicinal cannabis in patients with clinically-significant obstructive sleep apnea, according to a Monday Australian bourse filing.</p><p>It will examine the impact of 10 milligrams of tetrahydrocannabinol on obstructive sleep apnea severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes.</p><p>The trial targets the enrollment of 24 participants and is expected to open within the year. Recruitment is expected to begin in July.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ECS.AU","symbol_name":"ECS Botanics Holdings","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2549430799","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549430799","pubTimestamp":1751868937,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ECS Botanics Holdings (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of Western A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ECS.AU":"ECS Botanics Holdings","XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数","BK7502":"大麻概念","XKO.AU":"标普/澳交所 300指数","BK7096":"制药"},"translate_title":"ECS Botanics将提供胶囊用于试验研究药用大麻在阻塞性睡眠呼吸暂停患者中的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.83,"XJO.AU":0.83,"ECS.AU":0.9,"XAO.AU":0.83},"content_text":"ECS Botanics Holdings (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of Western Australia, to assess the therapeutic potential of medicinal cannabis in patients with clinically-significant obstructive sleep apnea, according to a Monday Australian bourse filing.It will examine the impact of 10 milligrams of tetrahydrocannabinol on obstructive sleep apnea severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes.The trial targets the enrollment of 24 participants and is expected to open within the year. Recruitment is expected to begin in July.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}